

RESEARCH ARTICLE

Clinical characteristics and predictors for in-hospital mortality in adult COVID-19 patients: A retrospective single center cohort study in Vilnius, Lithuania

Ieva Kubiliute¹*, Monika Vitkauskaitė², Jurgita Urbonienė³, Linas Svetikas¹, Birute Zablockiene¹, Ligita Jancoriene¹

1 Clinic of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, **2** Faculty of Medicine, Vilnius University, Vilnius, Lithuania, **3** Center of Infectious Diseases, Vilnius University Hospital Santaros Clinics, Vilnius, Lithuania

* These authors contributed equally to this work.

* ieva.kubiliute@santa.lt



OPEN ACCESS

Citation: Kubiliute I, Vitkauskaitė M, Urbonienė J, Svetikas L, Zablockiene B, Jancoriene L (2023) Clinical characteristics and predictors for in-hospital mortality in adult COVID-19 patients: A retrospective single center cohort study in Vilnius, Lithuania. *PLoS ONE* 18(8): e0290656. <https://doi.org/10.1371/journal.pone.0290656>

Editor: Reaz Mahmud, Dhaka Medical College and Hospital, BANGLADESH

Received: February 5, 2023

Accepted: August 11, 2023

Published: August 25, 2023

Copyright: © 2023 Kubiliute et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its [Supporting Information](#) files.

Funding: The authors received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

Abstract

Background

The COVID-19 infection had spread worldwide causing many deaths. Mortality rates and patients' characteristics varied within and between countries, making it important to understand the peculiarities of different populations. The aim of this study was to identify the main predictors associated with in-hospital mortality due to COVID-19 in Vilnius, Lithuania.

Materials and methods

This was a retrospective observational cohort study conducted at Vilnius University Hospital Santaros Clinics, Lithuania. The study included SARS-CoV-2 positive patients aged over 18 years and hospitalized between March 2020 and May 2021. Depersonalized data were retrieved from electronic medical records. The predictive values of laboratory parameters were evaluated using ROC analysis. Multivariable binary logistic regression was performed to reveal predictors of in-hospital mortality due to COVID-19.

Results

Among 2794 patients, 54.4% were male, the age median was 59 years (IQR 48–70), 47.4% had at least one comorbidity. The most common comorbidities were arterial hypertension (36.9%) and diabetes mellitus (13.7%). Overall, 12.7% of patients died. Multivariable regression revealed that age (OR 1.04, 95%CI 1.02–1.06), congestive heart failure (OR 3.06, 95%CI 1.96–4.77), obesity (OR 3.90, 95%CI 2.12–7.16), COPD (OR 2.92, 95%CI 1.12–7.60), previous stroke (OR 5.80, 95%CI 2.07–16.21), urea >7.01 mmol/l (OR 2.32, 95%CI 1.47–3.67), AST/ALT >1.49 (OR 1.54, 95%CI 1.08–2.21), LDH >452.5 U/l (OR 2.60, 95%CI 1.74–3.88), CRP >92.68 mg/l (OR 1.58, 95%CI 1.06–2.35), IL-6 >69.55 ng/l (OR 1.62, 95%

CI 1.10–2.40), and troponin I >18.95 ng/l (OR 2.04, 95%CI 1.38–3.02), were associated with increased risk for in-hospital mortality in COVID-19 patients.

Conclusions

Age, congestive heart failure, obesity, COPD, prior stroke, and increased concentration of urea, LDH, CRP, IL-6, troponin I, ALT to AST ratio were identified to be the predictors for in-hospital mortality of COVID-19 patients.

Introduction

In December 2019, the first atypical pneumonia cases of unknown etiology were identified in Wuhan City, China [1, 2]. The virus causing this disease was subsequently confirmed as belonging to the β group of coronaviruses and was described as Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses (ICTV) [3, 4]. Due to its rapid global spread, the World Health Organization (WHO) declared the outbreak of the novel coronavirus a pandemic on 11 March 2020 [5]. Over 169 million cases of COVID-19 infection have been confirmed worldwide by 1 June 2021, including more than 3.53 million deaths [6].

SARS-CoV-2 is mainly transmitted between people through respiratory droplets and aerosols [7]. The virus primarily targets tissues of both the upper and lower airway by utilizing angiotensin-converting enzyme (ACE2) and the transmembrane protease serine 2 (TMPRSS2) which are co-expressed in most epithelial cells of the human respiratory tract. COVID-19 has a broad spectrum of clinical manifestation, ranging from asymptomatic to severe disease with multiple organ failure [7, 8]. Hospitalization rates vary between 4 and 7% in different population settings [7]. Moreover, studies have found that up to 44% of hospitalized patients were admitted to the intensive care unit and at least one third of them died between March 2020 and January 2021 [9–12]. Patient characteristics and mortality rates vary substantially within and between countries and over time due to a lack of standardized testing strategies, different hospital admission criteria and unequal capacities of health care systems [13, 14]. The geriatric population, people with major comorbidities, and males were considered to be at higher risk of poor clinical outcome, longer hospital stays and higher mortality rate [15–17]. Patients with hypertension, diabetes mellitus, obesity and chronic kidney disease have been observed at the high risk for mortality in COVID-19 [13, 18]. These comorbidities are not only associated with a downregulation of immune system but also with a substantially increased expression of ACE2. The latter is known to accelerate the binding of the pathogenic virus to their target cells and enhance inflammatory response leading to a cytokine storm [18].

In Lithuania, the first case of SARS-CoV-2 infection was officially reported on 28 February 2020, and the first case of COVID-19 infection in the Vilnius region was reported on 13 March 2020 [19]. A total of 274 783 confirmed cases and nearly 4300 deaths have been reported until 1 June 2021 [20]. It is important to know clinical characteristics and factors associated with poor outcomes of COVID-19 patients in every region and country to create the effective patient monitoring and treatment strategy and provide individually and economically appropriate healthcare. To the best of the author's knowledge, this kind of data of Lithuanian population has not been published yet. Therefore, the aim of our study was to identify the main predictors associated with in-hospital mortality due to COVID-19 infection in Vilnius, Lithuania.

Materials and methods

Study design and setting

This is a retrospective observational cohort study conducted at a tertiary care university hospital Vilnius University Hospital Santaros Clinics, Vilnius, Lithuania. The objectives of our study were: to describe main clinical and initial laboratory characteristics of hospitalized COVID-19 positive patients, to obtain optimal cut-off values and predictive accuracy for in-hospital mortality due to COVID-19 infection of initial laboratory tests performed on admission and to identify the main predictors associated with in-hospital mortality due to COVID-19 infection.

Participants

Inclusion criteria were people older than 18 years who were hospitalized to any COVID-19 unit, including standard care, high dependency, or intensive care unit, in Vilnius University Hospital Santaros Clinics with confirmed COVID-19 infection between March 2020 and May 2021. The infection was confirmed by positive SARS-CoV-2 reverse transcriptase polymerase chain reaction or rapid antigen test in nasopharyngeal sample. The antigen test was used for symptomatic patients within 5 days from the onset of COVID-19 symptoms.

Data collection and variables

Depersonalized data were retrieved from electronic Vilnius University Hospital Santaros Clinics medical records and were provided by Informatics and development center of Vilnius University Hospital Santaros Clinics in accordance with hospital-approved procedures.

Demographic variables included gender and age. Data about comorbidities included: arterial hypertension (coded as I10; I11.0; I11.9 according to the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM)), diabetes mellitus without complications (E10.9, E11.9), diabetes mellitus with complications (E10, E11 except for E10.9, E11.9), obesity (E66, E66.0, E66.2, E66.8, E66.9), chronic kidney disease (N18.1, N18.2, N18.3, N18.4, N18.5, N18.9), heart failure (I50.0, I50.1, I50.9), HIV infection (B23.8, B20), viral hepatitis C (B18.2), viral hepatitis B (B18.1), chronic obstructive pulmonary disease (COPD) (J44.0, J44.1, J44.8, J44.9), previous stroke (I69), previous myocardial infarction (I25.2), coronary artery disease (I20.0, I20.2, I20.8, I20.9), organ transplantation (Z94.0, Z94.1, Z94.4). If underlying condition was not registered by these ICD-10-AM codes in patient medical records during hospitalization due to COVID-19, the patient was considered as not having that condition.

Information about used medications (antibiotics, systemic steroids, antivirals), required invasive mechanical ventilation, and length of hospitalization was also obtained from depersonalized electronic medical records.

The results of initial laboratory tests that were performed upon admission to hospital, including complete blood count, glucose, creatinine, urea, sodium, potassium, alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin, interleukin 6 (IL-6), D-dimer, fibrinogen, troponin I, were also extracted and evaluated.

The main outcome in this study was in-hospital mortality. Therefore, the patients were distributed into two groups according to their outcome. Patients who died during the hospitalization due to COVID-19 infection were included in the 'Lethal outcome' group. Patients who were discharged or transferred to another hospital or nursing care facility were included into 'Non-lethal outcome' group.

Statistical analysis

Continuous variables are presented as median (interquartile range (IQR)). For categorical variables, absolute and relative frequencies were calculated. Mann-Whitney U test was used to compare continuous variables, and χ^2 test, or Fisher's exact test was used to compare categorical variables. The predictive value of laboratory parameters was evaluated by measuring the area under the receiver operating characteristic (ROC) curve. The optimal cut-off value was obtained by calculating the Youden index (sensitivity + specificity - 1). To explore the predictors associated with in-hospital mortality due to COVID-19, univariable and multivariable binary logistic regression models were created. Comorbidities statistically significantly associated with in-hospital mortality in univariable analysis, age, gender, and concentration of laboratory tests analytes with highest established predictive accuracy (as a categorical variable dichotomized according to the cut-off value) were included into multivariable analysis. Odds ratio (OR), 95% confidence interval (CI) were reported for logistic regression. Sensitivity analysis was conducted by calculating E-value for OR and lower limit of CI [21]. p -value < 0.05 indicated statistical significance. IBM Statistical Package for the Social Sciences software version 20.0 was used for statistical analysis.

Ethical aspects

The study was conducted in accordance with the Declaration of Helsinki. In this study, only depersonalized and pseudonymized data provided by Informatics and development center of Vilnius University Hospital Santaros Clinics in accordance with hospital-approved procedures were analyzed. For this reason, no bioethics approval is required for this study. The need for participant consent was waived because only depersonalized and strictly pseudonymized data was analyzed. Vilnius University Hospital Santaros Clinics have confirmed that data processing for this biomedical research was carried out and this publication was released under the Law on the Ethics of Biomedical Research of the Republic of Lithuania (2022-12-13; No. SR-7021).

Results

Demographic, clinical, and laboratory characteristics of hospitalized COVID-19 patients

Overall, 2794 hospitalized COVID-19 positive adults were included in this study. The flow chart of patient selection is presented in Fig 1.

Among 2794 hospitalized patients, 54.4% were male. The median age was 59 (IQR 48–70) years, and 49.4% of patients were 60 years old and older (Fig 2).

Almost half of the patients ($n = 1323/2794$, 47.4%) had at least one underlying medical condition. The most frequent comorbidities were arterial hypertension ($n = 1030/2794$, 36.9%) and diabetes mellitus ($n = 382/2794$, 13.7%) (Table 1). The proportion of patients with underlying medical conditions increased with age reaching 75% of patients at age of 80 years and older (Fig 2). Prevalence of arterial hypertension, coronary artery disease, congestive heart failure, COPD, chronic kidney disease, stroke, previous transplant, HIV infection, viral hepatitis B and C did not differ between males and females. Obesity and diabetes mellitus were more prevalent among females than males (obesity 5.5% vs 3.9%, $p = 0.043$ and diabetes mellitus 16.1% vs 11.6%, $p = 0.001$, respectively).

A total of 1931/2794 (69.1%) patients were treated with antibiotics (Table 1). The combinations of amoxicillin/clavulanic acid and piperacillin/tazobactam were the most frequently administered antibiotics given to 81.2% (1568/1931) and 32.5% (627/1931) of patients




Fig 1. The flow chart of patient selection.

<https://doi.org/10.1371/journal.pone.0290656.g001>




Fig 2. Distribution of patients and comorbidities, and case fatality rate of patients by age.

<https://doi.org/10.1371/journal.pone.0290656.g002>

Table 1. Demographic, clinical, and therapeutic characteristics of hospitalized COVID-19 patients by outcome.

Characteristic	Total (N = 2794), n (%)	Non-lethal outcome (N = 2438), n (%)	Lethal outcome (N = 356), n (%)	p-value
Age in years, median (IQR)	59 (48–70)	58 (47–67)	72.5 (62–81)	<0.001
Male	1520 (54.4)	1324 (54.3)	196 (55.1)	0.791
Female	1274 (45.6)	1114 (45.7)	160 (44.9)	0.791
Comorbidities				
Any underlying condition	1323 (47.4)	1045 (42.9)	278 (78.1)	<0.001
Arterial hypertension	1030 (36.9)	835 (34.2)	195 (54.8)	<0.001
Coronary artery disease	105 (3.8)	73 (3.0)	32 (9.0)	<0.001
Congestive heart failure	220 (7.9)	117 (4.8)	103 (28.9)	<0.001
Diabetes mellitus	382 (13.7)	297 (12.2)	85 (23.9)	<0.001
Diabetes mellitus with no complications	111 (4.0)	105 (4.3)	6 (1.7)	0.018
Diabetes mellitus with complications	272 (9.7)	193 (7.9)	79 (22.2)	<0.001
Obesity	129 (4.6)	88 (3.6)	41 (11.5)	<0.001
COPD	44 (1.6)	27 (1.1)	17 (4.8)	<0.001
Chronic kidney disease	215 (7.7)	153 (6.3)	62 (17.4)	<0.001
Previous stroke	39 (1.4)	19 (0.8)	20 (5.6)	<0.001
Transplant recipient	32 (1.1)	26 (1.1)	6 (1.7)	0.287
HIV infection	4 (0.1)	4 (0.2)	0 (0.0)	1.000
Viral hepatitis B	14 (0.5)	12 (0.5)	2 (0.6)	0.697
Viral hepatitis C	6 (0.2)	6 (0.2)	0 (0.0)	1.000
Complications				
Sepsis	219 (7.8)	67 (2.7)	152 (42.7)	<0.001
Acute kidney injury	296 (10.6)	112 (4.6)	184 (51.7)	<0.001
Acute myocardial infarction	47 (1.7)	40 (1.6)	7 (2.0)	0.655
Acute pulmonary embolism	63 (2.3)	45 (1.8)	18 (5.1)	<0.001
Acute stroke	39 (1.4)	30 (1.2)	9 (2.5)	0.052
Treatment				
Invasive mechanical ventilation	225 (8.1)	56 (2.3)	169 (47.5)	<0.001
Antibiotics	1931 (69.1)	1659 (68.0)	272 (76.4)	0.001
None	863 (30.9)	779 (32.0)	84 (23.6)	<0.001
One	1165 (41.7)	1060 (43.5)	105 (29.5)	
Two	471 (16.9)	400 (16.4)	71 (19.9)	
Three or more	295 (10.6)	199 (8.2)	96 (27.0)	
Antivirals (Remdesivir)	820 (29.3)	752 (30.8)	68 (19.1)	<0.001
Systemic steroids	1679 (60.1)	1452 (59.6)	227 (63.8)	0.130
Length of hospitalization in days, median (IQR)	11 (7–16)	11 (7–16)	12 (5.25–19)	0.360

COPD—chronic obstructive pulmonary disease; HIV—human immunodeficiency virus; IQR—interquartile range.

<https://doi.org/10.1371/journal.pone.0290656.t001>

receiving antibiotics, respectively. Median duration of treatment with amoxicillin/clavulanic acid was 7 (IQR 4–10) days, and with piperacillin/tazobactam— 8 (IQR 5–11) days. Sixty per cent of patients (1679/2794, 60.1%) received systemic steroids, 96.8% (1625/1679) of them received dexamethasone. Median duration of treatment with dexamethasone was 8 (IQR 5–10) days. Almost one-third of patients (820/2794, 29.3%) were treated with remdesivir for 5 (IQR 5–5) days. Remdesivir was administered intravenously as a 200 mg dose on day 1, followed by a 100 mg dose on days 2 through 5. Out of all the patients treated with remdesivir, 78% (640/820) completed full treatment regimen. Among 2794 hospitalized patients, 8.1% (225/2794) required invasive mechanical ventilation. Sepsis was diagnosed in 7.8% (219/2794)

Table 2. Initial laboratory characteristics of hospitalized COVID-19 patients by outcome.

Variable	All patients		Non-lethal outcome		Lethal outcome		p-value
	n	Value, median (IQR)	n	Value, median (IQR)	n	Value, median (IQR)	
Hemoglobin, g/L	2794	137 (123–149)	2438	138 (125–149)	356	127 (111–145)	<0.001
WBC, $\times 10^9/L$	2794	6.58 (4.89–9.25)	2438	6.43 (4.83–8.77)	356	8.56 (5.67–12.00)	<0.001
Neutrophils, $\times 10^9/L$	2794	4.84 (3.33–7.30)	2438	4.67 (3.24–6.80)	356	6.96 (4.38–10.28)	<0.001
Lymphocytes, $\times 10^9/L$	2794	1.00 (0.70–1.41)	2438	1.04 (0.75–1.48)	356	0.72 (0.50–1.10)	<0.001
NLR	2791	4.69 (2.80–8.12)	2437	4.40 (2.69–7.28)	354	8.85 (4.61–17.70)	<0.001
Platelets, $\times 10^9/L$	2794	199.0 (155.0–259.0)	2438	200.5 (157.0–260.0)	356	192.0 (143.0–255.8)	0.010
Glucose, mmol/L	2589	6.18 (5.50–7.35)	2268	6.11 (5.45–7.11)	321	7.16 (6.03–9.39)	<0.001
Creatinine, $\mu\text{mol/L}$	2741	81.00 (66.00–104.11)	2386	80.00 (65.24–97.66)	355	110.00 (78.00–170.29)	<0.001
Urea, mmol/L	2509	5.77 (4.14–8.90)	2157	5.38 (3.99–7.66)	352	11.67 (7.10–20.68)	<0.001
Sodium, mmol/L	2743	140.00 (137.00–143.00)	2386	140.00 (137.00–143.00)	357	138.00 (134.95–142.00)	<0.001
Potassium, mmol/L	2743	4.2 (3.9–4.6)	2386	4.2 (3.9–4.5)	357	4.3 (3.9–4.8)	0.003
ALT, U/L	2647	31.04 (19.00–52.00)	2312	31.20 (19.85–51.96)	335	31.00 (17.00–55.00)	0.669
AST, U/L	2629	36.00 (25.21–57.00)	2293	35.00 (25.00–53.00)	336	51.81 (31.09–78.75)	<0.001
AST to ALT ratio	2629	1.18 (0.88–1.68)	2292	1.13 (0.85–1.57)	334	1.69 (1.19–2.49)	<0.001
LDH, U/L	2404	303 (235–411)	2113	294 (231–392)	291	417 (298–626)	<0.001
CRP, mg/L	2775	59.60 (19.90–123.00)	2419	53.30 (17.50–111.80)	356	118.40 (58.53–183.43)	<0.001
Ferritin, $\mu\text{g/L}$	2351	481.50 (236.26–1019.25)	2143	447.51 (224.00–954.00)	319	717.00 (366.60–1687.24)	<0.001
IL-6, ng/L	2351	29.50 (14.30–57.40)	2041	27.00 (13.50–52.25)	310	55.15 (26.18–122.50)	<0.001
D-dimer, $\mu\text{g/L}$	2436	522.50 (310.00–1045.00)	2112	480.00 (290.00–888.75)	324	1080.00 (560.00–2158.75)	<0.001
Fibrinogen, g/L	2146	5.42 (4.47–6.53)	1853	5.39 (4.51–6.46)	293	5.68 (4.12–6.93)	0.400
Troponin I, ng/L	2179	10.00 (5.18–27.00)	1897	9.00 (5.00–20.65)	282	41.00 (15.75–173.50)	<0.001

ALT–alanine aminotransferase; AST–aspartate aminotransferase; CRP–C-reactive protein; IL-6 –interleukin 6; IQR–interquartile range; LDH–lactate dehydrogenase; NLR–neutrophil-to-lymphocyte ratio; WBC–white blood cell count.

Reference values: hemoglobin: 128–160 g/L (for males), 117–145 g/L (for females); WBC: 4.0–9.8 $\times 10^9/L$; neutrophils: 1.5–6.0 $\times 10^9/L$; lymphocytes: 1.0–4.0 $\times 10^9/L$; NLR– 1–2 [22]; platelets: 140–450 $\times 10^9/L$; glucose: 4.2–6.1 mmol/L; creatinine: 64–104 $\mu\text{mol/L}$ (for males), 49–90 $\mu\text{mol/L}$ (for females); urea: 2.5–7.5 mmol/L; sodium: 134–145 mmol/L; potassium: 3.8–5.3 mmol/L; ALT: ≤ 40 U/L; AST: ≤ 40 U/L; AST to ALT ratio: < 1 ; LDH: 125–243 U/L; CRP: < 5 mg/L; ferritin: 25–350 $\mu\text{g/L}$ (for men), 13–232 $\mu\text{g/L}$ (for women); IL-6: 0–7 ng/L; D-dimer: < 250 $\mu\text{g/L}$; fibrinogen: 2–4 g/L; troponin I: < 19 ng/L.

<https://doi.org/10.1371/journal.pone.0290656.t002>

of patients, acute kidney injury occurred in 10.6% (296/2794), acute myocardial infarction–in 1.7% (47/2794), acute pulmonary embolism–in 2.3% (63/2794), and stroke affected 1.4% (39/2794) of patients during hospitalization.

The median length of hospitalization was 11 (IQR 7–16) days. Four-fifths of patients (2240/2794, 80.2%) were discharged home, 7.1% (198/2794) of patients were transferred to another hospital or nursing home, 12.7% (356/2794) of patients died. Case fatality rate increased with age from 1.6% in patients under the age of forty to 37.1% in patients at age of eighty years and older (Fig 2).

Initial laboratory results and the comparison of their medians by outcome groups are summarized in Table 2.

Clinical and laboratory characteristics associated with lethal outcome of COVID-19 patients

Compared with patients in non-lethal group, patients with lethal outcome during hospitalization were older (72.5 (62–81) years vs 58 (47–67) years, $p < 0.001$), and more often had comorbidities such as arterial hypertension (54.8% vs 34.2%, $p < 0.001$), coronary artery disease (9.0% vs 3.0%, $p < 0.001$), congestive heart failure (28.9% vs 4.8%, $p < 0.001$), diabetes mellitus (23.9%

vs 12.2%, $p < 0.001$), obesity (11.5% vs 3.6%, $p < 0.001$), COPD (4.8% vs 1.1%, $p < 0.001$), chronic kidney disease (17.4% vs 6.3%, $p < 0.001$), and prior stroke (5.6% vs 0.8%, $p < 0.001$) (Table 1).

On admission, patients with lethal outcome had higher levels of white blood cell count (WBC), neutrophil count, neutrophil-to-lymphocyte ratio (NLR), glucose, creatinine, urea, potassium, AST to ALT ratio, LDH, CRP, ferritin, IL-6, D-dimer, and troponin I compared to those in non-lethal group. Whereas, haemoglobin concentration, lymphocytes count, platelets, and sodium concentration were significantly lower in non-survivors. Only the medians of ALT and fibrinogen concentrations did not differ between these groups. These differences are detailed and presented in Table 2.

The area under the ROC curve (AUC) were calculated to evaluate predictive accuracy of laboratory tests for lethal outcome. These results are presented in Table 3 and Fig 3. Urea possessed the highest predictive accuracy with AUC 0.80 (95% confidence interval (CI) 0.77–0.82), NLR, creatinine, AST to ALT ratio, LDH, D-dimer, and troponin I demonstrated good predictive accuracy with AUC ≥ 0.70 , CRP, and IL-6 showed fair predictive accuracy with AUC 0.68 (95% CI 0.65–0.71) and 0.69 (95% CI 0.66–0.72), respectively. Optimal cut-off values were calculated and are shown in Table 3.

Predictors for COVID-19 in-hospital mortality

Univariable analysis revealed that age, arterial hypertension, coronary artery disease, congestive heart failure, diabetes mellitus, obesity, COPD, chronic kidney disease, and previous stroke were associated with in-hospital mortality in patients with COVID-19 (Table 4).

Table 3. Predictive accuracy for in-hospital mortality of initial laboratory tests performed upon admission.

Variable	AUC (95% CI)	p-value	Cut-off value	Reference value
Hemoglobin, g/L	0.40 (0.36–0.43)	<0.001	172.5	128–160 (for males) 117–145 (for females)
WBC, $\times 10^9/L$	0.63 (0.60–0.67)	<0.001	8.09	4.0–9.8
Neutrophils, $\times 10^9/L$	0.66 (0.62–0.69)	<0.001	6.16	1.5–6.0
Lymphocytes, $\times 10^9/L$	0.34 (0.31–0.37)	<0.001	3.07	1.0–4.0
NLR	0.71 (0.68–0.74)	<0.001	5.71	1–2 [22]
Platelets, $\times 10^9/L$	0.46 (0.42–0.49)	0.010	332.5	140–450
Glucose, mmol/L	0.66 (0.62–0.69)	<0.001	7.07	4.2–6.1
Creatinine, $\mu\text{mol/L}$	0.70 (0.66–0.73)	<0.001	98.97	64–104 (for males) 49–90 (for females)
Urea, mmol/L	0.80 (0.77–0.82)	<0.001	7.01	2.5–7.5
Sodium, mmol/L	0.40 (0.36–0.43)	<0.001	150.7	134–145
Potassium, mmol/L	0.55 (0.51–0.58)	0.003	4.68	3.8–5.3
ALT, U/L	0.49 (0.46–0.53)	0.669	102.5	≤ 40
AST, U/L	0.65 (0.62–0.68)	<0.001	55.92	≤ 40
AST to ALT ratio	0.70 (0.67–0.73)	<0.001	1.49	<1
LDH, U/L	0.70 (0.67–0.74)	<0.001	452.50	125–243
CRP, mg/L	0.68 (0.65–0.71)	<0.001	92.86	<5
Ferritin, $\mu\text{g/L}$	0.63 (0.59–0.66)	<0.001	483.34	25–350 (for men) 13–232 (for women)
IL-6, ng/L	0.69 (0.66–0.72)	<0.001	69.55	0–7
D-dimer, $\mu\text{g/L}$	0.72 (0.69–0.75)	<0.001	687.5	<250
Fibrinogen, g/L	0.52 (0.48–0.56)	0.400	7.51	2–4
Troponin I, ng/L	0.77 (0.74–0.80)	<0.001	18.95	<19

ALT—alanine aminotransferase; AST—aspartate aminotransferase; AUC—area under the ROC curve; CI—confidence interval; CRP—C-reactive protein; IL-6—interleukin 6; LDH—lactate dehydrogenase; NLR—neutrophil-to-lymphocyte ratio; WBC—white blood cell count.

<https://doi.org/10.1371/journal.pone.0290656.t003>




Fig 3. Predictive accuracy for in-hospital mortality of initial laboratory tests performed upon admission, ROC curve. ALT–alanine aminotransferase; AST–aspartate aminotransferase; LDH–lactate dehydrogenase; NLR–neutrophil-to-lymphocyte ratio.

<https://doi.org/10.1371/journal.pone.0290656.g003>

Multivariable analysis confirmed that age (OR 1.04, 95% CI 1.02–1.06), congestive heart failure (OR 3.06, 95% CI 1.96–4.77), obesity (OR 3.90, 95% CI 2.12–7.16), COPD (OR 2.92, 95% CI 1.12–7.60), previous stroke (OR 5.80, 95% CI 2.07–16.21) and the following laboratory parameters: urea >7.01 mmol/l (OR 2.32, 95% CI 1.47–3.67), AST to ALT ratio >1.49 (OR 1.54, 95% CI 1.08–2.21), LDH >452.5 U/l (OR 2.60, 95% CI 1.74–3.88), CRP > 92.68 mg/l (OR 1.58, 95% CI 1.06–2.35), IL-6 > 69.55 ng/l (OR 1.62, 95% CI 1.10–2.40), and troponin I >18.95 ng/l (OR 2.04, 95% CI 1.38–3.02) are independent predictors for in-hospital mortality of patients with COVID-19 (Table 4, Fig 4). The E-value was calculated and attested the robustness of predictors and in-hospital mortality association regarding bias caused by potential unmeasured confounders (Table 4).

Univariable and multivariable analyses were repeated in subgroups stratified by sex and by age (Fig 5). In multivariable analysis age, obesity, urea >7.01 mmol/L, and LDH >452.5 U/L were associated with higher risk for in-hospital mortality in patients of both genders, while congestive heart failure (OR 4.83, CI 95% 2.68–8.71) and COPD (OR 4.29, CI 95% 1.44–12.78) were identified as predictors only in male COVID-19 patients, and previous stroke (OR 10.46, CI 95% 2.26–48.32), IL-6 > 69.55 ng/L (OR 2.31, CI 95% 1.23–4.30) and troponin I >18.95 ng/L (OR 2.98, CI 95% 1.64–5.42)—only in female patients.

Multivariable analysis of subgroups by age revealed that congestive heart failure, obesity, urea >7.01 mmol/L, and troponin I >18.95 ng/L were associated with in-hospital mortality of COVID-19 patients in both groups—patients aged 60 years or younger and patients over 60 years old. Coronary artery disease (OR 15.98, 95% CI 1.56–163.93), IL-6 > 69.55 ng/L (OR 4.81, 95% CI 2.06–11.27) were identified as predictors for in-hospital mortality in COVID-19 patients aged 60 years and below, while age (OR 1.05, 95% CI 1.03–1.08), COPD (OR 2.69, 95% CI 1.02–7.11), previous stroke (OR 5.59, 95% CI 2.03–15.35), AST to ALT ratio >1.49

Table 4. Predictors associated with in-hospital mortality of hospitalized patients with COVID-19.

Characteristic	Univariable regression		Multivariable regression		E-value for OR; for CI lower limit
	OR (95% CI)	p-value	OR (95% CI)	p-value	
Age in years	1.07 (1.06–1.08)	<0.001	1.04 (1.02–1.06)	<0.001	1.24; 1.16
Male	1.03 (0.82–1.29)	0.791	0.84 (0.58–1.20)	0.329	-
Comorbidities					
Arterial hypertension	2.33 (1.86–2.91)	<0.001	0.79 (0.55–1.15)	0.224	-
Coronary artery disease	3.20 (2.08–4.93)	<0.001	1.19 (0.62–2.26)	0.601	-
Congestive heart failure	8.08 (6.01–10.85)	<0.001	3.06 (1.96–4.77)	<0.001	5.57; 3.33
Diabetes mellitus	2.26 (1.72–2.97)	<0.001	0.92 (0.60–1.43)	0.717	-
Obesity	3.48 (2.36–5.13)	<0.001	3.90 (2.12–7.16)	<0.001	7.26; 3.66
COPD	4.48 (2.42–8.30)	<0.001	2.92 (1.12–7.60)	0.029	5.29; 1.49
Chronic kidney disease	3.15 (2.29–4.33)	<0.001	1.00 (0.59–1.68)	0.997	-
Previous stroke	7.58 (4.00–14.35)	<0.001	5.80 (2.07–16.21)	<0.001	11.08; 3.56
Transplant recipient	1.59 (0.65–3.89)	0.309	-	-	-
Viral hepatitis B	1.15 (0.26–5.18)	0.851	-	-	-
Laboratory analytes					
NLR > 5.71	4.10 (3.22–5.22)	<0.001	1.09 (0.75–1.60)	0.647	-
Creatinine > 98.97, $\mu\text{mol/L}$	4.58 (3.64–5.78)	<0.001	1.23 (0.79–1.90)	0.361	-
Urea > 7.01, mmol/L	7.72 (5.94–10.03)	<0.001	2.32 (1.47–3.67)	<0.001	4.07; 2.30
AST to ALT ratio > 1.49	3.92 (3.09–4.97)	<0.001	1.54 (1.08–2.21)	0.018	2.54; 1.37
LDH > 452.5, U/L	4.82 (3.72–6.25)	<0.001	2.60 (1.74–3.88)	<0.001	4.64; 2.87
CRP > 92.68, mg/L	3.60 (2.86–4.53)	<0.001	1.58 (1.06–2.35)	0.024	2.54; 1.31
IL-6 > 69.55, ng/L	4.42 (3.43–5.70)	<0.001	1.62 (1.10–2.40)	0.015	2.62; 1.43
D-dimer > 687.5, $\mu\text{g/L}$	4.67 (3.62–6.02)	<0.001	1.14 (0.78–1.66)	0.492	-
Troponin I > 18.95, ng/L	7.11 (5.38–9.41)	<0.001	2.04 (1.38–3.02)	<0.001	3.5; 2.1

ALT–alanine aminotransferase; AST–aspartate aminotransferase; CI–confidence interval; COPD–chronic obstructive pulmonary disease; CRP–C-reactive protein; IL-6 –interleukin 6; LDH–lactate dehydrogenase; NLR–neutrophil-to-lymphocyte ratio; OR–odds ratio.

Reference values: NLR– 1–2 [22]; creatinine: 64–104 $\mu\text{mol/L}$ (for males), 49–90 $\mu\text{mol/L}$ (for females); urea: 2.5–7.5 mmol/L ; AST to ALT ratio: <1; LDH: 125–243 U/L; CRP: <5 mg/L ; IL-6: 0–7 ng/L ; D-dimer: <250 $\mu\text{g/L}$; troponin I: <19 ng/L .

<https://doi.org/10.1371/journal.pone.0290656.t004>

(OR 1.73, 95% CI 1.15–2.58), LDH >452.5 U/L (OR 2.81, 95% CI 1.75–4.49), and CRP > 92.68 mg/L (OR 1.70, 95% CI 1.08–2.70) were also associated with in-hospital mortality in patients older than 60 years old.

Discussion

In this retrospective study, we report the patient characteristics and predictors associated with in-hospital mortality among hospitalized COVID-19 patients in one of the main tertiary care hospitals in the country. This is one of the few studies on this topic conducted in Eastern Europe and particularly in the Baltic region. This study contributes to the knowledge of the natural course of SARS-CoV-2 infection and how gender, age, underlying conditions, and laboratory characteristics are associated with the outcomes of the disease. We identified age, congestive heart failure, obesity, COPD, prior stroke, and increased concentration of urea (> 7.01 mmol/L), LDH (> 452.5 U/L), CRP (> 92.68 mg/L), IL-6 (> 69.55, ng/L), troponin I (> 18.95 ng/L), ALT to AST ratio (> 1.49) to be predictors for in-hospital mortality of COVID-19 patients. These predictors slightly differed between patient groups by sex and age.




Fig 4. Significant predictors associated with in-hospital mortality in patients with COVID-19, multivariable logistic regression model. ALT–alanine aminotransferase; AST–aspartate aminotransferase; CI–confidence interval; COPD–chronic obstructive pulmonary disease; CRP–C-reactive protein; IL-6 –interleukin 6; LDH–lactate dehydrogenase; OR–odds ratio.

<https://doi.org/10.1371/journal.pone.0290656.g004>

We found the in-hospital mortality to be 12.7%, which was close to Fakhri et al. research (13%) conducted in the US [23] and lower than published by Gujski et al. in Poland (18.4%) [24]. Other studies done in the Netherlands, United Kingdom, Germany reported in-hospital mortality to be 24.6%, 26%, 17.9%, respectively [13, 25, 26]. It also should be noted that in-hospital mortality differed during separate COVID-19 waves and in different populations [27–29].




Fig 5. Significant predictors associated with in-hospital mortality in patients with COVID-19, stratified by age and sex, multivariable logistic regression models. (A) Predictors associated with in-hospital mortality in female COVID-19 patients. (B) Predictors associated with in-hospital mortality in male COVID-19 patients. (C) Predictors associated with in-hospital mortality in COVID-19 patients aged 60 years and younger. (D) Predictors associated with in-hospital mortality in COVID-19 patients aged over 60 years. ALT–alanine aminotransferase; AST–aspartate aminotransferase; CI–confidence interval; COPD–chronic obstructive pulmonary disease; CRP–C-reactive protein; IL-6 –interleukin 6; LDH–lactate dehydrogenase; OR–odds ratio.

<https://doi.org/10.1371/journal.pone.0290656.g005>

Gray et al. revealed that in-hospital mortality rates were lower in the second wave compared to the first for all socioeconomic and demographic groups [27]. In addition, in-hospital mortality was 15.1%, 12.6%, 12.8% during the first, the second and the third waves of COVID-19 in Spain, and 9.5%, 10.2%, 5.4% in Switzerland, respectively [28, 29]. On the contrary, Gujski et al. noted a higher fatality rate during the second COVID-19 wave in Poland (8.3% vs 21%) [24], which could be linked to an increased number of hospitalized patients during the second wave. Unfortunately, we could not distinguish the separate COVID-19 waves to compare the mortality rates and patient characteristics, since we did not identify different SARS-CoV-2 strains and we can only hypothesize that our study period included B.1.1.280, B.1.177.60, alpha (B.1.1.7), and B.1.620 variants.

Lower mortality could be a possible result of introduction of interventions such as remdesivir, dexamethasone, high-use of thromboprophylaxis, as well as ventilation management, and the start of COVID-19 vaccination program [30, 31]. Despite declining mortality rates, advanced age, male sex, and pre-existing comorbidity remained a key mortality risk factors among COVID-19 patients [27–29].

Consistent with other studies [25, 32–35], we found that advanced age is an independent predictor for in-hospital mortality associated with 4% increase in odds ratio per each year. This tendency could be explained by the fact that older people have more comorbidities which themselves are risk factors for in-hospital mortality of COVID-19 patients [18, 36]. This also could be due to immunosenescence, characterized by impaired age-dependent defects in T-cell and B-cell function, which weaken immune responses to most viruses, including SARS-CoV-2 [37]. Although, numerous studies have reported that males are at higher risk of severe COVID-19 infection, as well as of death, especially over 65 years [33, 38, 39], we found that 55.1% of fatal cases were male but males did not appear to have a significantly higher in-hospital mortality risk.

Docherty et al. established that up to 77.5% of hospitalized COVID-19 patients had at least one comorbidity [13]. Additionally, Thakur et al. disclosed that arterial hypertension, obesity, and diabetes mellitus were the most prevalent comorbidities [40], accounting for up to 51.3%, 35.0%, and 49.8% of cases, respectively [23, 41]. In our study, 47.4% of patients had at least one underlying condition with the most prevalent being arterial hypertension (36.9%) and diabetes mellitus a second (13.7%). Different from other researches [23, 32, 42], the prevalence of obesity in our study was considerably lower (4.6%). This difference could be related to the fact that we analyzed depersonalized database and obesity might be not encoded in patients' medical records during this hospitalization. Patients with comorbidities are not only more vulnerable to COVID-19 infection, but underlying conditions act as triggers for increased risk of fatality [18, 36]. We observed that comorbidity was significantly associated with fatal outcome. Moreover, multivariable analysis identified congestive heart failure, obesity, COPD, and previous stroke as predictors for in-hospital mortality. While analysing the results stratified by sex, we discovered that cardiovascular and chronic lung diseases were associated with higher in-hospital mortality in men. These results are in contrast to the findings of Fernández-Martínez et al. [43] and could be linked to gender-related lifestyle differences.

We found that the presence of congestive heart failure 3.06 times increased the risk of in-hospital mortality in general population and in both groups stratified by age. Increased mortality in congestive heart failure patients is associated with dysregulation of intracellular calcium handling system, therefore COVID-19 infection causes hypoxia induced excessive intracellular calcium that culminate in apoptosis of cardiac myocyte [44]. A global meta-analysis by Popkin et al. demonstrated that obesity increased COVID-19 mortality by 1.48 times [45], whereas we found that in-hospital mortality was 3.90-fold higher in obese patients. Obesity also remained significant in subgroup analysis by sex and by age. Not only does obesity lead to an increased

expression of inflammatory molecules, but also reduces thoracic wall compliance and functional residual capacity, promoting the development of acute respiratory distress syndrome related lung damage in patients with COVID-19 [46–48]. Our study showed that COPD increased in-hospital mortality in COVID-19 patients by 2.92-fold and in male patients population-by 4.29-fold. Pranata et al. also found that COVID-19 patients with COPD had a 4.36 times higher rate of death [49]. This is due to an increased expression of ACE2 in COPD epithelial cells, reduced antiviral responses (especially interferons), and the potential for secondary bacterial infection [50, 51]. We also found that previous stroke increased in-hospital mortality by 5.80 times, however the results must be taken with caution given the wide confidence interval. The relationship between death and previous stroke might be due to lasting disabilities in this group [52]. Tehrani et al. suggested that patients with a history of stroke carry a predisposition that, under the impact of COVID-19 induced coagulopathy, may lead to vascular events causing fatal outcome [52].

In this study, there were significant differences in the initial laboratory parameters between patients with lethal and non-lethal outcomes, indicating higher levels of inflammation, cell-turnover and metabolic dysregulation in the first group [53]. Many studies have investigated the role of various biomarkers in determining prognosis for patients with COVID-19 and evidenced that routine laboratory parameters have important clinical application value in predicting the course of COVID-19 [54–56]. Since the beginning of the pandemic, CPR, ferritin, LDH and D-dimer have been widely used for risk stratification, however there is marked diversity in cut-off values [39, 57, 58].

Our study results demonstrated that NLR, urea, creatinine, AST to ALT ratio, LDH, D-dimer, CRP, IL-6 and troponin I demonstrated good predictive accuracy for in-hospital mortality. Multivariable analysis confirmed elevated urea, AST to ALT ratio, LDH, CRP, IL-6, and troponin I together with age and presence of comorbidities described above to be predictors for in-hospital mortality.

The results of this study indicated that increased concentration of urea (above 7.01 mmol/L) was significantly associated with in-hospital mortality increasing these odds 2.32 times and it also remained a significant predictor in further subgroup analysis by sex and age. A study conducted in China on 12,413 patients had evidenced association of elevated blood urea nitrogen (BUN) and elevated serum creatinine with all-cause in-hospital mortality risk, respectively BUN adjusted hazard ratio (aHR) was 6.27, and serum creatinine aHR was 2.65 [59]. Moreover, Liu YM et al. reported elevated BUN level to show a more significant association with adverse outcomes than serum creatinine suggesting that the elevation in BUN level not only indicates a kidney dysfunction, but it can also reflect inflammatory status, catabolism, and renal hypoperfusion from hypovolemia, sepsis, or reduced cardiac output while serum creatinine mainly represents a status of kidney injury and metabolic disturbance [59].

Furthermore, our research demonstrated that AST to ALT ratio has better predictive accuracy for in-hospital mortality than AST or ALT separately, and patients with AST to ALT ratio >1.49 had 54% higher odds for lethal outcome. Consistent results were reported in other studies [60–62].

This study revealed elevated LDH, CRP and IL-6 to be also associated with an increased risk of in-hospital mortality. Patients with LDH >452.5 U/L on admission had 2.6 times higher odds for in-hospital mortality. In a pooled analysis of nine published studies conducted by Henry et al. which included 1532 patients with COVID-19, elevated LDH levels were associated with 6-fold increased odds of developing severe disease and 16-fold increased odds of mortality that is much higher compared to our results [63]. Our findings indicated that CRP >92.68 mg/L and IL-6 >69.55 ng/L were the optimal cut-off values discriminating patients with lethal and non-lethal outcome. Both CRP and IL-6 remained predictors for in-hospital

mortality in multivariable analysis that increased this risk for 58% and 62%, respectively. In multiple studies exploring routine laboratory parameters in COVID-19 patients, increased CRP levels and IL-6 were also reported in severe patients when compared to non-severe patients [64–67].

Moreover, we identified that patients with troponin I concentration above 18.95 ng/L had 2.04 times higher risk for in-hospital lethal outcome. Other studies also found out increased level of troponin to be associated with this outcome [68, 69]. The meta-analysis of 12,262 COVID-19 patients indicated that increased troponin concentration was detected in 31% of patients and they had 4.75 times higher odds for mortality [70].

The combination of patient medical history and routine laboratory tests are simple, and cost-effective indicators that can be used to identify COVID-19 patients at a greater risk of death. The presence of these predictors might assist in choosing of medical care and treatment for COVID-19 patients individually.

Bias/limitations

Data for this study was retrieved from strictly pseudonymized and depersonalized electronic medical records based on encoded medical information. For this reason, there is a probability that some information about patients could be not mentioned or missed in their medical records or were encoded in any other code that was not extracted from electronic database. Furthermore, we could not extract the data about addictions, vaccination status, COVID-19 pandemic wave etc. and include these variables into analysis. It indicates the need of further prospective research of COVID-19 positive patients' cohorts to get more accurate and extensive results.

As in this study we included all hospitalized COVID-19 positive adults despite their comorbidities, some laboratory test results (e.g., urea, troponin I, AST to ALT ratio) could be increased not only because of the COVID-19 infection itself, but also due to comorbidities. Therefore, the identified predictors of in-hospital mortality could be determined not only by factors caused by COVID-19 disease, but the consequences of the general condition. In the context of COVID-19 disease, laboratory markers (e.g., urea, creatinine, AST, ALT, CRB, LDH, troponin I) serve as indicators of disease severity and prognosis, while it should be recognized that these markers can be influenced by other underlying conditions, especially in hospitalized patients with COVID-19.

Conclusions

The predictors for in-hospital mortality of COVID-19 patients were identified to be age, congestive heart failure, obesity, COPD, prior stroke, and increased concentration of urea, LDH, CRP, IL-6, troponin I, ALT to AST ratio. This study evidenced that the history of comorbidities and routine laboratory tests can be beneficial identifying COVID-19 patients at increased risk of death and choosing the best medical care strategy.

Supporting information

S1 Data.
(XLS)

Acknowledgments

The authors thank Mindaugas Paulauskas and Oleg Aliancevic for the great help in collaborating with Informatics and Development Center of Vilnius University Hospital Santaros Clinics and designing the format of depersonalized database.

Author Contributions

Conceptualization: Ieva Kubiliute, Jurgita Urboniene, Ligita Jancoriene.

Data curation: Jurgita Urboniene.

Formal analysis: Ieva Kubiliute, Jurgita Urboniene.

Investigation: Ieva Kubiliute, Jurgita Urboniene.

Methodology: Ieva Kubiliute, Jurgita Urboniene.

Supervision: Ligita Jancoriene.

Visualization: Ieva Kubiliute, Jurgita Urboniene.

Writing – original draft: Ieva Kubiliute, Monika Vitkauskaitė, Jurgita Urboniene.

Writing – review & editing: Jurgita Urboniene, Linas Svetikas, Birute Zablockiene, Ligita Jancoriene.

References

1. World Health Organization. Pneumonia of unknown cause—China; Available from: <https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON229>
2. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. *J Med Virol*. 2020; 92(4):401–2. <https://doi.org/10.1002/jmv.25678> PMID: 31950516
3. World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it; Available from: [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-\(covid-2019\)-and-the-virus-that-causes-it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it)
4. Gorbalenya AE, Baker SC, Baric R, Groot RJ de, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses—a statement of the Coronavirus Study Group. 2020 Feb 11; <https://doi.org/10.1038/s41564-020-0695-z>
5. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19—11 March 2020; Available from: <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020>
6. World Health Organization. COVID-19 weekly epidemiological update, edition 42, 1 June 2021. World Health Organization; 2021 Jun. Available from: <https://apps.who.int/iris/handle/10665/341622>
7. Salzberger B, Buder F, Lampl B, Ehrenstein B, Hitzenbichler F, Holzmann T, et al. Epidemiology of SARS-CoV-2. *Infection*. 2021; 49(2):233–9. <https://doi.org/10.1007/s15010-020-01531-3> PMID: 33034020
8. Alfi O, Yakirevitch A, Wald O, Wandel O, Izhar U, Oiknine-Djian E, et al. Human Nasal and Lung Tissues Infected Ex Vivo with SARS-CoV-2 Provide Insights into Differential Tissue-Specific and Virus-Specific Innate Immune Responses in the Upper and Lower Respiratory Tract. *J Virol*. 2021 Jun 24; 95(14):10.1128/jvi.00130-21. <https://doi.org/10.1128/JVI.00130-21> PMID: 33893170
9. Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden of SARS-CoV-2 in France. *Science*. 2020 Jul 10; 369(6500):208–11. <https://doi.org/10.1126/science.abc3517> PMID: 32404476
10. Abate SM, Ahmed Ali S, Mantfardo B, Basu B. Rate of Intensive Care Unit admission and outcomes among patients with coronavirus: A systematic review and Meta-analysis. *PLoS ONE*. 2020 Jul 10; 15(7):e0235653. <https://doi.org/10.1371/journal.pone.0235653> PMID: 32649661
11. Guillon A, Laurent E, Godillon L, Kimmoun A, Grammatico-Guillon L. In-hospital mortality rates of critically ill COVID-19 patients in France: a nationwide cross-sectional study of 45 409 ICU patients. *Br J Anaesth*. 2021 Nov 1; 127(5):e180–2. <https://doi.org/10.1016/j.bja.2021.08.006> PMID: 34503830

12. Ceccato A, Pérez-Arnal R, Motos A, Barbé F, Torres A, Saera MB, et al. One-year mortality after ICU admission due to COVID-19 infection. *Intensive Care Med.* 2022 Mar 1; 48(3):366–8. <https://doi.org/10.1007/s00134-021-06611-y> PMID: 35041016
13. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *The BMJ.* 2020 May 22; 369:m1985. <https://doi.org/10.1136/bmj.m1985> PMID: 32444460
14. Yoo JY, Dutra SVO, Fanfan D, Sniffen S, Wang H, Siddiqui J, et al. Comparative analysis of COVID-19 guidelines from six countries: a qualitative study on the US, China, South Korea, the UK, Brazil, and Haiti. *BMC Public Health.* 2020 Dec 3; 20:1853. <https://doi.org/10.1186/s12889-020-09924-7> PMID: 33272250
15. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet.* 2020 Mar 28; 395(10229):1054–62. [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3) PMID: 32171076
16. Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. *Crit Care.* 2020 Apr 28; 24(1):179. <https://doi.org/10.1186/s13054-020-02902-w> PMID: 32345311
17. Garg S, Patel K, Pham H, Whitaker M, O'Halloran A, Milucky J, et al. Clinical Trends Among U.S. Adults Hospitalized With COVID-19, March to December 2020. *Ann Intern Med.* 2021 Aug 10;M21–1991. <https://doi.org/10.7326/M21-1991> PMID: 34370517
18. Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. *Intervirology.* 2021; 64(1):36–47. <https://doi.org/10.1159/000512592> PMID: 33296901
19. Ministry of Health of the Republic of Lithuania. First coronavirus case confirmed in Lithuania. Available from: <https://lrv.lt/en/news/first-coronavirus-case-confirmed-in-lithuania>
20. Worldometer. Lithuania COVID—Coronavirus Statistics—Worldometer. Available from: <https://www.worldometers.info/coronavirus/country/lithuania/>
21. VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. *Ann Intern Med.* 2017 Aug 15; 167(4):268–74. <https://doi.org/10.7326/M16-2607> PMID: 28693043
22. Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. *Bratisl Lek Listy.* 2021; 122(7):474–88. https://doi.org/10.4149/BLL_2021_078 PMID: 34161115
23. Fakhri MG, Ottenbacher A, Yehia B, Fogel R, Miller C, Winegar A, et al. COVID-19 hospital prevalence as a risk factor for mortality: an observational study of a multistate cohort of 62 hospitals. *BMJ Qual Saf.* 2022 Jan; 31(1):45–53. <https://doi.org/10.1136/bmjqs-2021-013721> PMID: 34611041
24. Gujski M, Jankowski M, Rabczenko D, Goryński P, Juszczyk G. Characteristics and Clinical Outcomes of 116,539 Patients Hospitalized with COVID-19—Poland, March–December 2020. *Viruses.* 2021 Aug; 13(8):1458. <https://doi.org/10.3390/v13081458> PMID: 34452324
25. Nijman G, Wientjes M, Ramjith J, Janssen N, Hoogerwerf J, Abbink E, et al. Risk factors for in-hospital mortality in laboratory-confirmed COVID-19 patients in the Netherlands: A competing risk survival analysis. *PLOS ONE.* 2021 Mar 26; 16(3):e0249231. <https://doi.org/10.1371/journal.pone.0249231> PMID: 33770140
26. Hobohm L, Sagoschen I, Barco S, Schmidtman I, Espinola-Klein C, Konstantinides S, et al. Trends and Risk Factors of In-Hospital Mortality of Patients with COVID-19 in Germany: Results of a Large Nationwide Inpatient Sample. *Viruses.* 2022 Feb; 14(2):275. <https://doi.org/10.3390/v14020275> PMID: 35215869
27. Gray WK, Navaratnam AV, Day J, Wendon J, Briggs TWR. COVID-19 hospital activity and in-hospital mortality during the first and second waves of the pandemic in England: an observational study. *Thorax.* 2021 Nov 24. <https://doi.org/10.1136/thoraxjnl-2021-218025> PMID: 34819384
28. Roso-Llorach A, Serra-Picamal X, Cos FX, Pallejà-Millán M, Mateu L, Rosell A, et al. Evolving mortality and clinical outcomes of hospitalized subjects during successive COVID-19 waves in Catalonia, Spain. *Glob Epidemiol.* 2022 Dec 1; 4:100071. <https://doi.org/10.1016/j.gloepi.2022.100071> PMID: 35018339
29. Diebold M, Martinez AE, Adam KM, Bassetti S, Osthoff M, Kassi E, et al. Temporal trends of COVID-19 related in-hospital mortality and demographics in Switzerland—a retrospective single centre cohort study. *Swiss Med Wkly.* 2021 Jul 29;(29). <https://doi.org/10.4414/smw.2021.20572> PMID: 34324697
30. Jassat W, Mudara C, Ozougwu L, Tempia S, Blumberg L, Davies MA, et al. Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study. *Lancet Glob Health.* 2021 Sep 1; 9(9):e1216–25. [https://doi.org/10.1016/S2214-109X\(21\)00289-8](https://doi.org/10.1016/S2214-109X(21)00289-8) PMID: 34252381

31. Muthukrishnan J, Vardhan V, Mangalesh S, Koley M, Shankar S, Yadav AK, et al. Vaccination status and COVID-19 related mortality: A hospital based cross sectional study. *Med J Armed Forces India*. 2021 Jul 1; 77:S278–82. <https://doi.org/10.1016/j.mjafi.2021.06.034> PMID: 34334894
32. Fried MW, Crawford JM, Mospan AR, Watkins SE, Munoz Hernandez B, Zink RC, et al. Patient Characteristics and Outcomes of 11,721 Patients with COVID-19 Hospitalized Across the United States. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2020 Aug 28;ciaa1268. <https://doi.org/10.1093/cid/ciaa1268> PMID: 32856034
33. Sargin Altunok E, Satıcı C, Dinc V, Kamat S, Alkan M, Demirkol MA, et al. Comparison of demographic and clinical characteristics of hospitalized COVID-19 patients with severe/critical illness in the first wave versus the second wave. *J Med Virol*. 2022; 94(1):291–7. <https://doi.org/10.1002/jmv.27319> PMID: 34491575
34. Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. *J Med Virol*. 2021; 93(3):1449–58. <https://doi.org/10.1002/jmv.26424> PMID: 32790106
35. Meister T, Pisarev H, Kolde R, Kalda R, Suija K, Milani L, et al. Clinical characteristics and risk factors for COVID-19 infection and disease severity: A nationwide observational study in Estonia. *PLOS ONE*. 2022 Jun 16; 17(6):e0270192. <https://doi.org/10.1371/journal.pone.0270192> PMID: 35709192
36. Zhang J jin, Dong X, Liu G hui, Gao Y dong. Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality. *Clin Rev Allergy Immunol*. 2022 Jan 19;1–18. <https://doi.org/10.1007/s12016-022-08921-5> PMID: 35044620
37. Bartleson JM, Radenkovic D, Covarrubias AJ, Furman D, Winer DA, Verdin E. SARS-CoV-2, COVID-19 and the aging immune system. *Nat Aging*. 2021 Sep; 1(9):769–82. <https://doi.org/10.1038/s43587-021-00114-7> PMID: 34746804
38. Kragholm K, Andersen MP, Gerds TA, Butt JH, Østergaard L, Polcwiartek C, et al. Association Between Male Sex and Outcomes of Coronavirus Disease 2019 (COVID-19)—A Danish Nationwide, Register-based Study. *Clin Infect Dis*. 2021 Dec 1; 73(11):e4025–30. <https://doi.org/10.1093/cid/ciaa924> PMID: 32634827
39. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet*. 2020 Feb 15; 395(10223):507–13. [https://doi.org/10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7) PMID: 32007143
40. Thakur B, Dubey P, Benitez J, Torres JP, Reddy S, Shokar N, et al. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. *Sci Rep*. 2021 Apr 20; 11(1):8562. <https://doi.org/10.1038/s41598-021-88130-w> PMID: 33879826
41. Khamis F, Al Awaidey S, Shaaibi MA, Shukeili MA, Chhetri S, Balushi AA, et al. Epidemiological Characteristics of Hospitalized Patients with Moderate versus Severe COVID-19 Infection: A Retrospective Cohort Single Centre Study. *Diseases*. 2021 Dec 23; 10(1):1. <https://doi.org/10.3390/diseases10010001> PMID: 35076497
42. Palaiodimos L, Ali R, Teo HO, Parthasarathy S, Karamanis D, Chamorro-Pareja N, et al. Obesity, Inflammation, and Mortality in COVID-19: An Observational Study from the Public Health Care System of New York City. *J Clin Med*. 2022 Jan; 11(3):622. <https://doi.org/10.3390/jcm11030622> PMID: 35160073
43. Fernández-Martínez NF, Ortiz-González-Serna R, Serrano-Ortiz Á, Rivera-Izquierdo M, Ruiz-Montero R, Pérez-Contreras M, et al. Sex Differences and Predictors of In-Hospital Mortality among Patients with COVID-19: Results from the ANCOHVID Multicentre Study. *Int J Environ Res Public Health*. 2021 Jan; 18(17):9018. <https://doi.org/10.3390/ijerph18179018> PMID: 34501608
44. Dalia T, Lahan S, Ranka S, Acharya P, Gautam A, Goyal A, et al. Impact of congestive heart failure and role of cardiac biomarkers in COVID-19 patients: A systematic review and meta-analysis. *Indian Heart J*. 2021; 73(1):91–8. <https://doi.org/10.1016/j.ihj.2020.12.002> PMID: 33714416
45. Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH, et al. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. *Obes Rev*. 2020; 21(11):e13128. <https://doi.org/10.1111/obr.13128> PMID: 32845580
46. Kanneganti TD, Dixit VD. Immunological complications of obesity. *Nat Immunol*. 2012 Aug; 13(8):707–12. <https://doi.org/10.1038/ni.2343> PMID: 22814340
47. Leija-Martínez JJ, Huang F, Del-Río-Navarro BE, Sánchez-Muñoz F, Muñoz-Hernández O, Giacomani-Martínez A, et al. IL-17A and TNF- α as potential biomarkers for acute respiratory distress syndrome and mortality in patients with obesity and COVID-19. *Med Hypotheses*. 2020 Nov 1; 144:109935. <https://doi.org/10.1016/j.mehy.2020.109935> PMID: 32795834

48. Cai Z, Yang Y, Zhang J. Obesity is associated with severe disease and mortality in patients with coronavirus disease 2019 (COVID-19): a meta-analysis. *BMC Public Health*. 2021 Aug 4; 21(1):1505. <https://doi.org/10.1186/s12889-021-11546-6> PMID: 34348687
49. Pranata R, Soeroto AY, Huang I, Lim MA, Santoso P, Permana H, et al. Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19. *Int J Tuberc Lung Dis*. 2020 Aug 1; 24(8):838–43. <https://doi.org/10.5588/ijtld.20.0278> PMID: 32912389
50. Singh D, Mathioudakis AG, Higham A. Chronic obstructive pulmonary disease and COVID-19: interrelationships. *Curr Opin Pulm Med*. 2022 Mar; 28(2):76–83. <https://doi.org/10.1097/MCP.0000000000000834> PMID: 34690257
51. Jacobs M, Van Eeckhoutte HP, Wijnant SRA, Janssens W, Joos GF, Brusselle GG, et al. Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects. *Eur Respir J*. 2020 Aug 20; 56(2):2002378. <https://doi.org/10.1183/13993003.02378-2020> PMID: 32675207
52. Tehrani S, Killander A, Åstrand P, Jakobsson J, Gille-Johnson P. Risk factors for death in adult COVID-19 patients: Frailty predicts fatal outcome in older patients. *Int J Infect Dis*. 2021 Jan 1; 102:415–21. <https://doi.org/10.1016/j.ijid.2020.10.071> PMID: 33130213
53. Holler JG, Eriksson R, Jensen TØ, van Wijhe M, Fischer TK, Søgaaard OS, et al. First wave of COVID-19 hospital admissions in Denmark: a Nationwide population-based cohort study. *BMC Infect Dis*. 2021 Jan 9; 21:39. <https://doi.org/10.1186/s12879-020-05717-w> PMID: 33421989
54. Shahid MF, Malik A, Siddiqi FA, Fazal I, Hammad M, Saeed A, et al. Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count as Early Diagnostic Tools for Corona Virus Disease 2019. *Cureus*. 2022 Mar 5; 14(3). <https://doi.org/10.7759/cureus.22863> PMID: 35399415
55. Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. *J Med Virol*. 2020; 92(10):1733–4. <https://doi.org/10.1002/jmv.25819> PMID: 32242950
56. Al-Mazedi MS, Rajan R, Al-Jarallah M, et al. Neutrophil to lymphocyte ratio and in-hospital mortality among patients with SARS-CoV-2: A retrospective study. *Annals of Medicine and Surgery (2012)* 2022 Oct; 82:104748. 2022;104748. <https://doi.org/10.1016/j.amsu.2022.104748> PMID: 36212733
57. Qeadan F, Tingey B, Gu LY, Packard AH, Erdei E, Saeed AI. Prognostic Values of Serum Ferritin and D-Dimer Trajectory in Patients with COVID-19. *Viruses*. 2021 Mar 5; 13(3):419. <https://doi.org/10.3390/v13030419> PMID: 33807920
58. Khinda J, Janjua NZ, Cheng S, van den Heuvel ER, Bhatti P, Darvishian M. Association between markers of immune response at hospital admission and COVID-19 disease severity and mortality: A meta-analysis and meta-regression. *J Med Virol*. 2020 Aug 10; 10.1002/jmv.26411. <https://doi.org/10.1002/jmv.26411> PMID: 32776551
59. Liu YM, Xie J, Chen MM, Zhang X, Cheng X, Li H, et al. Kidney Function Indicators Predict Adverse Outcomes of COVID-19. *Med N Y N*. 2021 Jan 15; 2(1):38–48.e2. <https://doi.org/10.1016/j.medj.2020.09.001> PMID: 33043313
60. Zinellu A, Arru F, De Vito A, Sassu A, Valdes G, Scano V, et al. The De Ritis ratio as prognostic biomarker of in-hospital mortality in COVID-19 patients. *Eur J Clin Invest*. 2021; 51(1):e13427. <https://doi.org/10.1111/eci.13427> PMID: 33043447
61. Qin C, Wei Y, Lyu X, Zhao B, Feng Y, Li T, et al. High aspartate aminotransferase to alanine aminotransferase ratio on admission as risk factor for poor prognosis in COVID-19 patients. *Sci Rep*. 2020 Oct 5; 10:16496. <https://doi.org/10.1038/s41598-020-73575-2> PMID: 33020546
62. Fu Y, Du S, Liu X, Cao L, Yang G, Chen H. A linear relationship between De Ritis ratio and mortality in hospitalized patients with COVID-19: A secondary analysis based on a large retrospective cohort study. *iLIVER*. 2022 Sep 1; 1(3):169–75. <https://doi.org/10.1016/j.liver.2022.08.002>
63. Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. *Am J Emerg Med*. 2020 Sep; 38(9):1722–6. <https://doi.org/10.1016/j.ajem.2020.05.073> PMID: 32738466
64. Tahir Huyut M, Huyut Z, Ilkbahar F, Mertoğlu C. What is the impact and efficacy of routine immunological, biochemical and hematological biomarkers as predictors of COVID-19 mortality? *Int Immunopharmacol*. 2022 Apr 1; 105:108542. <https://doi.org/10.1016/j.intimp.2022.108542> PMID: 35063753
65. Todor SB, Bîrluțiu V, Topîrcean D, Mihăilă RG. Role of biological markers and CT severity score in predicting mortality in patients with COVID-19: An observational retrospective study. *Exp Ther Med*. 2022 Sep 28; 24(5):698. <https://doi.org/10.3892/etm.2022.11634> PMID: 36277141
66. Pan F, Yang L, Li Y, Liang B, Li L, Ye T, et al. Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study. *Int J Med Sci*. 2020 May 18; 17(9):1281–92. <https://doi.org/10.7150/ijms.46614> PMID: 32547323

67. Guirao JJ, Cabrera CM, Jiménez N, Rincón L, Urra JM. High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19. *Mol Immunol*. 2020 Dec; 128:64–8. <https://doi.org/10.1016/j.molimm.2020.10.006> PMID: 33075636
68. Majure DT, Gruberg L, Saba SG, Kvasnovsky C, Hirsch JS, Jauhar R. Usefulness of Elevated Troponin to Predict Death in Patients With COVID-19 and Myocardial Injury. *Am J Cardiol*. 2021 Jan 1; 138:100–6. <https://doi.org/10.1016/j.amjcard.2020.09.060> PMID: 33058800
69. Salvatici M, Barbieri B, Cioffi SMG, Morengi E, Leone FP, Maura F, et al. Association between cardiac troponin I and mortality in patients with COVID-19. *Biomarkers*. 2020 Dec; 25(8):634–640. <https://doi.org/10.1080/1354750X.2020.1831609> PMID: 33003961
70. Wibowo A, Pranata R, Akbar MR, Purnomowati A, Martha JW. Prognostic performance of troponin in COVID-19: A diagnostic meta-analysis and meta-regression. *Int J Infect Dis*. 2021 Apr 1; 105:312–8. <https://doi.org/10.1016/j.ijid.2021.02.113> PMID: 33667694